←
André Zimerman1,171 posts
André Zimerman avatar

André Zimerman

@AndreZimerman

Head of Clinical Trials, @hospitalmoinhos 🇧🇷 | Professor, PG Cardiology, @ufrgsnoticias 🇧🇷 | Fellowship, @TIMIStudyGroup 🇺🇸 | Lipids, Trials, Cardiology

◷ Joined May 2016▧ 330 Photos and videos
André Zimerman avatar
André Zimerman@AndreZimerman·29 Aug 2025

Today, I had the honor to present PhysioSync-HF as a Late-Breaking Clinical Trial at #ESCCongress. Key message: In HFrEF and LBBB, conduction system pacing was *inferior* to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.

Post attachmentPost attachment
International Atherosclerosis Society (IAS) avatar
⟳ André Zimerman retweeted
International Atherosclerosis Society (IAS)@atherosociety·Oct 16

What a week at #WCC2026 and the 81st Brazilian Congress of Cardiology in Rio de Janeiro! 🇧🇷 It was great to see so many members of the IAS community together, presenting, chairing, and leading the conversation on inflammation and cardiovascular risk. 🎓 Inflammation Academy fellows took the stage, with Guilherme Gaia, MD, presenting his abstract and @AndreZimerman, MD, PhD, co-chairing the Lp(a) session alongside IAS Member @marciominame, MD, PhD. Inflammation Academy 2026 fellow Daniel Valle, MD, also joined the IAS delegation in Rio. 🦠 Together with GSK Brazil, IAS hosted a joint symposium on Viral-Induced Inflammation: Mechanisms and Cardiovascular Implications, moderated by Otávio Rizzi Coelho, MD, PhD, with IAS Immediate Past President Peter Libby, MD; Otávio Rizzi Coelho Filho, MD, PhD; and Rosana Richtmann, MD, PhD. 💉 IAS and @GSK Brazil also hosted a Masterclass on Vaccines Recommendations for CVD Patients with IAS Secretary Viviane @zorzanelli Rocha Giraldez, MD; and Peter Libby, MD. 🫀 IAS Board Member Ioanna Gouni-Berthold, MD, presented on the efficacy and safety of intensive cholesterol-lowering therapy, bempedoic acid in clinical practice, and risk enhancers in primary prevention. IAS voices were also featured across sessions on Lp(a), dyslipidemia, and residual cardiovascular risk. 🤝 The week also strengthened IAS partnerships across the region. IAS joined the @worldheartfed Regional Roundtable on Improving Lipid Management in Latin America and welcomed leaders from the Inter-American Society of Cardiology (SIAC) to dinner, including @SIAC_cardio President Ricardo López Santi, MD; SIAC Past President Fernando Wyss, MD, PhD, FACC; and Patricio López-Jaramillo, MD, PhD. Thank you to everyone who joined us, and to @rauldsf_santos, MD, PhD, MSc; Rodrigo @KarleziAlonso, MD, PhD; Sarah Fagundes Grobe, MD, PhD; Maria Cristina Izar, MD, PhD; Paulo Behr, MD, MSc; Fabiana Hanna Rached, MD, PhD; Henrique Tria Bianco, MD, PhD; Renato Jorge Alves, MD, PhD; and Andrei Sposito, MD, PhD, for sharing their expertise. Até a próxima, Rio! 💙 #WorldCongressOfCardiology #CBC2026 #Inflammation #CardiovascularHealth #Lpa

Post attachmentPost attachmentPost attachmentPost attachment
Margarida Pujol Lopez avatar
⟳ André Zimerman retweeted
Margarida Pujol Lopez@MargaridaPujol·Aug 29

CRT crossovers discussion was very enriching. Don’t see it as a failure. You may fail, but you provide best possible care to the patient. LOTCRT? Are we designing well trials? Always love discussions with @kvernooy in the room. It reminds me my PhD defense @AndreZimerman #ESC26

Post attachmentPost attachmentPost attachmentPost attachment

#ESCCongress 2026 🇩🇪🗺️ Conduction system pacing replacing biventricular cardiac resynchronisation therapy? an evidence-based 2026 algorithm Does the current evidence support CSP 🌿over BiVP 📘 and for heart failure prevention 🏥💦? True CSP or LBBAP umbrella ☔️ @uazmedphx

Post attachment
1:35
Cardiology Today avatar
⟳ André Zimerman retweeted
Cardiology Today@CardiologyToday·Jun 11

In patients with severe hypertriglyceridemia, olezarsen reduced triglycerides and risk for acute pancreatitis events compared with placebo at 12 months. #EAS2026 @EASCongress @AndreZimerman @ionispharma vist.ly/57dbr

André Zimerman avatar
André Zimerman@AndreZimerman·May 21

One of my favorite projects at TIMI. While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA. Now in @CircAHA @PrakritiGaba @marstonMD @BrianBergmark @TIMIStudyGroup

#Research letter: Earlier initiation of the PCSK9 inhibitor Evolocumab reduced the risk of arterial aneurysm events compared with delayed initiation in an analysis of the FOURIER trial ahajrnls.org/3PCdvbV

Post attachment
TIMI Study Group avatar
⟳ André Zimerman retweeted
TIMI Study Group@TIMIStudyGroup·Apr 23

We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.

Post attachment
JAMA Cardiology avatar
⟳ André Zimerman retweeted
JAMA Cardiology@JAMACardio·22 Dec 2025

Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease. ja.ma/49iZoiR

Post attachment
André Zimerman avatar
André Zimerman@AndreZimerman·24 Nov 2025

These findings suggest that, with olpasiran, apoB particles normally destined to form Lp(a) are either not secreted into circulation or more efficiently cleared, providing context for interpreting results of ongoing trials of Lp(a)-lowering agents. Link: jamanetwork.com/journals/jam…

André Zimerman avatar
André Zimerman@AndreZimerman·24 Nov 2025

How do Lp(a)-lowering agents affect atherogenic lipoproteins more broadly? In our @JAMACardio study, we show that olpasiran, an siRNA targeting apo(a), reduced Lp(a) in >95% without increasing non-Lp(a) particles. apoB was ultimately reduced by ~18%. @TIMIStudyGroup

Post attachmentPost attachment
JAMA Cardiology avatar
⟳ André Zimerman retweeted
JAMA Cardiology@JAMACardio·5 Nov 2025

Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease. ja.ma/4qqkClo

Post attachment